Showing 4701-4710 of 7112 results for "".
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has
- Belotero Now Available Nationwidehttps://practicaldermatology.com/news/20121106-ha-based_dermal-filler_released_by_merz/2459684/Belotero Balance, a dermal filler for the correction of moderate-to-severe facial wrinkles and folds, is now available nationwide from Merz Aesthetics. This dermal filler joins the Merz Aesthetics portfolio of injectable products, includin
- LEO Pharma's Taclonex Topical Suspension Approved for Body Plaqueshttps://practicaldermatology.com/news/20121029-leo_pharma_receives_fda_approval_for_taclonex_topical_suspension/2459689/LEO Pharma Inc. announced the US Food and Drug Administration (FDA) approval of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is
- Medical Entrepreneur Symposium Adds Breakout Sessionhttps://practicaldermatology.com/news/20121024-medical_entrepreneur_symposium_adds_breakout_session/2459693/The Medical Entrepreneur Symposium, a unique educational meeting for physicians, their office managers, and executives in healthcare, has added a breakout session for physician entrepreneurs wanting to take great business ideas or medical devices to market. Dr. Arlen Meyers will be the course direct
- Sanofi, Coca-Cola Begin Drink Projecthttps://practicaldermatology.com/news/20121018-sanofi_coca-cola_begin_drink_project/2459700/Sanofi and Coca-Cola are collaborating on a line of drinks, called Beautific Oenobiol, that will claim to offer improved skin, stronger hair, and increased vitality. The collaboration will begin with four products made with mineral water, fruit juice, and nutritional ingredients to be sold in French
- Restoration Robotics, Inc. Appoints Cary Rayment to Board of Directorshttps://practicaldermatology.com/news/20121015-restoration_robotics_inc_appoints_cary_rayment_to_board_of_directors/2459706/Cary Rayment joined the Board of Directors of Restoration Robotics, Inc.. He previously served as President and Chief Executive Officer of Alcon, Inc. until 2009 and then as non-executive chairman and director of Alcon, Inc.
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca
- Aesthetics Course Offers Cosmetic Practitioners Practical Business Advicehttps://practicaldermatology.com/news/20121002-aesthetics_course_offers_cosmetic_practitioners_practical_business_advice/2459724/Registration is now open for “Mastering the Business of Aesthetics” (MBA), a one-day course that teaches vital lessons regarding the financial components of cosmetic practice. The course will take place in Beverly Hills, CA on October 27th and cover topics such as optimizing laser business, increasi
- Valeant Acquires Medicis Pharmaceutical Corp. for $2.6 Billionhttps://practicaldermatology.com/news/20120904-valeant_acquires_medicis_pharmaceutical_for_26_billion/2459743/Valeant Pharmaceuticals announced an agreement to acquire Medicis Pharmaceutical for $44 per share in cash, in a deal worth approximately $2.6 billion. The transaction is expected to close in the first half of 2013 and has been approved by each company's board of directors. The combined operations w